Fulvestrant

Generic Name
Fulvestrant
Brand Names
Faslodex, Fulvestrant Mylan
Drug Type
Small Molecule
Chemical Formula
C32H47F5O3S
CAS Number
129453-61-8
Unique Ingredient Identifier
22X328QOC4
Background

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...

Indication

For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Associated Therapies
-

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

Phase 3
Completed
Conditions
Interventions
First Posted Date
2005-10-19
Last Posted Date
2012-06-06
Lead Sponsor
AstraZeneca
Target Recruit Count
51
Registration Number
NCT00241449
Locations
🇬🇧

Research Site, York, United Kingdom

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2005-09-22
Last Posted Date
2015-04-16
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
17
Registration Number
NCT00217464
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-20
Last Posted Date
2018-07-26
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
40
Registration Number
NCT00201864
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2005-09-16
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
4
Registration Number
NCT00183963
Locations
🇺🇸

Norris Comprehensive Cancer Center, Los Angeles, California, United States

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2005-09-07
Last Posted Date
2007-12-21
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
35
Registration Number
NCT00146601
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Lowell General Hospital, Lowell, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

Not Applicable
Conditions
First Posted Date
2005-08-04
Last Posted Date
2013-11-06
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
100
Registration Number
NCT00126464
Locations
🇺🇸

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States

Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-01-07
Last Posted Date
2019-03-05
Lead Sponsor
Translational Oncology Research International
Target Recruit Count
108
Registration Number
NCT00100854
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2004-12-14
Last Posted Date
2024-10-07
Lead Sponsor
AstraZeneca
Target Recruit Count
736
Registration Number
NCT00099437
Locations
🇻🇪

Research Site, Caracas, Venezuela

Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2004-09-29
Last Posted Date
2008-06-12
Lead Sponsor
AstraZeneca
Target Recruit Count
179
Registration Number
NCT00093002
Locations
🇬🇧

Research Site, Edinburgh, United Kingdom

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

First Posted Date
2004-05-19
Last Posted Date
2018-11-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
33
Registration Number
NCT00082810
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

© Copyright 2024. All Rights Reserved by MedPath